ArticleApplied biochemistry and biotechnology2026
Eco-Friendly Selenium Nanoparticle Strategy Against Staphylococcus Aureus Biofilm Formation.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amorphous selenium nanoparticles: synthesis strategies and multifunctional applications.RSC advances · 2026Review
- Green-synthesized metal oxide nanoparticles enhance the antibacterial activity of Portulaca oleracea through foliar nano-elicitation.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Biological synthesis of nanoparticles provides an eco-friendly method for producing bioactive materials characterized by low toxicity and enhanced bioavailability. In this study, selenium nanoparticles (SeNPs) were synthesized using the viable cell filtrate of Staphylococcus haemolyticus. Biosynthesis with bacterial cell filtrate uses extracellular enzymes, proteins, and metabolites as reducing and capping agents to convert a selenium precursor (commonly sodium selenite, Na₂SeO₃) into elemental selenium nanoparticles (Se⁰). Advantages include mild conditions, eco-friendliness, and often improved biocompatibility. Characterized by UV-Vis spectroscopy, X-ray diffraction (XRD), atomic force microscopy (AFM), field emission scanning electron microscopy (FE-SEM), energy-dispersive X-ray spectroscopy (EDX), and zeta potential analysis. The antimicrobial potential of SeNPs was assessed against biofilm-forming Staphylococcus aureus using a microdilution MIC assay. The SeNPs exhibited broad-spectrum activity, effectively inhibiting Gram-positive and Gram-negative bacteria, as well as Candida species. They also demonstrated strong antioxidant activity and low cytotoxicity, highlighting their safety profile. Furthermore, synergistic assays revealed that combining SeNPs with conventional antimicrobials enhanced their inhibitory effects, including against multidrug-resistant strains. At the molecular level, the clfB gene was detected by PCR, and real-time PCR revealed significant modulation of its expression following SeNP treatment, suggesting interference with biofilm formation. Cytotoxicity assays further indicated that SeNPs exhibited low toxicity toward normal fibroblast (HdFn) cells while showing improved anticancer activity against PC3 cells compared to free drug or neat selenium nanoparticles.
Indexed as
Identifiers
41504840What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.